Theravance Biopharma (TBPH) Gross Profit (2013 - 2018)

Theravance Biopharma (TBPH) has 6 years of Gross Profit data on file, last reported at $7.5 million in Q1 2018.

• Gross Profit for Q1 2018 came in at $7.5 million, up 197.11% year-over-year; the trailing twelve-month figure through Mar 2018 was $14.3 million (down 53.25% YoY), and the FY2017 annual result was $9.4 million, down 22.72% from the prior year.
• Gross Profit rose to $7.5 million in Q1 2018 per TBPH's latest filing, from $1.4 million in the prior quarter.
• Over five years, Gross Profit peaked at $20.0 million in Q1 2015 and troughed at -$1.8 million in Q4 2014.
• A 5-year average of $6.3 million and a median of $4.5 million in 2016 frame the typical range for Gross Profit.
• On a YoY basis, Gross Profit climbed as much as 53800.0% in 2014 and fell as far as 1122.29% in 2014.
• A 5-year view of Gross Profit shows it stood at -$1.8 million in 2014, then jumped by 138.68% to $692000.0 in 2015, then surged by 556.94% to $4.5 million in 2016, then plunged by 69.23% to $1.4 million in 2017, then surged by 435.6% to $7.5 million in 2018.
• Business Quant data shows TBPH's Gross Profit at $7.5 million in Q1 2018, $1.4 million in Q4 2017, and $3.3 million in Q3 2017.